Preliminary experience with yttrium-90-labeled Rituximab (chimeric anti-CD20 antibody) in patients with relapsed and refractory B-cell NHL - a prospective trial

被引：0
|
作者：
Thakral, P. [1 ]
Lata, S. [1 ]
Singla, S. [1 ]
Sharma, A. [1 ]
Bal, C. [1 ]
Malhotra, A. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP690
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [1] Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
    Knox, SJ
    Goris, ML
    Trisler, K
    Negrin, R
    Davis, T
    Liles, TM
    GrilloLopez, A
    Chinn, P
    Varns, C
    Ning, SC
    Fowler, S
    Deb, N
    Becker, M
    Marquez, C
    Levy, R
    CLINICAL CANCER RESEARCH, 1996, 2 (03) : 457 - 470
  • [2] Radiolabelling and quality control of anti-CD20 antibody-rituximab with 90Yttrium for the treatment of relapsed and refractory large B-cell NHL
    Thakral, P.
    Malhotra, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S301 - S301
  • [3] Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
    Thakral, Parul
    Singla, Suhas
    Vashist, Atul
    Yadav, Madhav P.
    Gupta, Santosh K.
    Tyagi, Jaya S.
    Sharma, Atul
    Bal, Chandra S.
    Snehlata
    Malhotra, Arun
    CURRENT RADIOPHARMACEUTICALS, 2016, 9 (02) : 160 - 168
  • [4] (90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma
    Davis, TA
    Goris, ML
    Trisler, KD
    Negrin, R
    Liles, TM
    Fowler, SF
    Deb, N
    Becker, M
    Marquez, CM
    Ning, S
    Levy, R
    Knox, S
    BLOOD, 1995, 86 (10) : 1080 - 1080
  • [5] Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
    Phuong Vo
    Gooley, Ted
    Rajendran, Joseph G.
    Fisher, Darrell R.
    Orozco, Johnnie J.
    Green, Damian J.
    Gopal, Ajay K.
    Haaf, Robyn
    Nartea, Margaret
    Storb, Rainer
    Appelbaum, Frederick R.
    Press, Oliver W.
    Pagel, John M.
    Sandmaier, Brenda M.
    HAEMATOLOGICA, 2020, 105 (06) : 1731 - 1737
  • [6] UBLITUXIMAB (TG-1101), A NOVEL ANTI-CD20 MONOCLONAL FOR RITUXIMAB RELAPSED/REFRACTORY B-CELL MALIGNANCIES
    Deng, C.
    Amengual, J.
    Schreeder, M.
    Pauli, E.
    Cutter, K.
    Sportelli, P.
    Miskin, H.
    O'Connor, O.
    HAEMATOLOGICA, 2013, 98 : 139 - 139
  • [7] UBLITUXIMAB (TG-1101), A NOVEL ANTI-CD20 MONOCLONAL FOR RITUXIMAB RELAPSED/REFRACTORY B-CELL MALIGNANCIES
    O'Connor, O. A.
    Schreeder, M. T.
    Deng, C.
    Amengual, J. E.
    Boccia, R.
    Khalil, M. Y.
    Mahadevan, D.
    Nikolinakos, P.
    Patterson, M.
    Pauli, E. K.
    Cutter, K.
    Mackenzie, M.
    DiSilvestre, C.
    Moon, A.
    Brotherton, M.
    Sportelli, P.
    Miskin, H. P.
    Farber, C. M.
    HAEMATOLOGICA, 2014, 99 : 142 - 143
  • [8] Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
    Tobinai, K
    Kobayashi, Y
    Narabayashi, M
    Ogura, M
    Kagami, Y
    Morishima, Y
    Ohtsu, T
    Igarashi, T
    Sasaki, Y
    Kinoshita, T
    Murate, T
    ANNALS OF ONCOLOGY, 1998, 9 (05) : 527 - 534
  • [9] The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia
    Jacoub, J
    Mchlayeh, W
    Tabbara, I
    Dave, HP
    Siegel, R
    Schechter, GP
    BLOOD, 2004, 104 (11) : 74B - 74B
  • [10] Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders
    Trapè, G
    Fianchi, L
    Lai, M
    Laurenti, L
    Piscitelli, R
    Leone, G
    Pagano, L
    HAEMATOLOGICA, 2003, 88 (02) : 223 - 225
12345